上海昀怡健康科技发展

Shanghai Yunyi Health Technology Development is a Chinese biotechnology company focused on the research and development of innovative therapeutics, particularly in oncology. The company's lead candidate is PE0105, a recombinant human anti-PD-1 monoclonal antibody currently being evaluated in Phase 1/2 clinical trials, including combination studies with PE0116 (a 4-1BB agonist). Shanghai Yunyi is controlled by Michael Xin Hui (founder of ChemPartner/ShangPharma) and his family, and operates in close collaboration with other group entities such as Shanghai Huaiyue Biotechnology and ChemPartner. The company's broader research interests and patent portfolio cover targets such as PI3K, GPR40, c-Met, and JAK.